ESPN+ Is Offering One Of Its Biggest Discounts Ever Right Now
Calling all avid sports fans: There's a more affordable way to stay plugged into the latest games this month. ESPN+ is offering one of its best streaming deals yet from now until June 20. New and eligible returning customers can sign up for just $4.99 per month for three months—over 50% off. This ESPN+ deal offers a less costly way to explore the service before committing to the standard $11.99 monthly fee.
With the ESPN+ subscription, you'll get access to live sports, original shows and exclusive coverage across major events for the NFL, MLB, NHL and UFC. Below, we've outlined how to unlock a discounted membership this month and answered some frequently asked questions about the subscription plan.
An ESPN+ subscription typically costs $11.99 per month or $119.99 per year. Occasionally, the streaming service will offer discounts on memberships, like the current offer of $4.99 per month for the first three months. For those looking to get even more value for their money, a basic bundle including ESPN+, Disney+ and Hulu is available for $16.99 per month. A premium, ad-free version of the same three-service bundle is also offered at $26.99 per month.
Those with an ESPN+ subscription will gain access to live sports, exclusive original content and additional features such as fantasy sports tools, premium articles and content across ESPN's digital platforms. Subscribers can stream events from the UFC, NHL, NFL, MLB and college sports spanning over 20 conferences.
ESPN+ does not currently offer a standalone free trial, but there is an alternative way to try out the streaming service for free. Simply sign up for a three-day free trial of Hulu + Live TV, which includes access to ESPN+. It's a smart way to explore the platform before committing to a standalone ESPN+ subscription or a Hulu + Live TV plan, which starts at $82.99 per month for the basic, ad-supported membership.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
25 minutes ago
- Yahoo
CRISPR Therapeutics (NasdaqGM:CRSP) Sees 16% Stock Price Surge Over Last Month
CRISPR Therapeutics experienced a 15.8% increase in its share price over the past month. While specific recent news on the company was not available to credit for this movement, it's worth noting that during this period, the broader market rose by 1.8%, and has seen a 13% increase over the past year. With market earnings projected to grow 14% annually, the strong performance of CRISPR's stock could be viewed alongside these generally positive trends and any recent but unspecified developments as contributing factors to its upward momentum in the market. Be aware that CRISPR Therapeutics is showing 1 weakness in our investment analysis. Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave. Over the past year, CRISPR Therapeutics' shares experienced a total return of 27.67% decline. This longer-term performance contrasts with the U.S. market's return of 12.6% and the U.S. Biotechs industry return of 9% over the same period. Despite the recent 15.8% increase in CRISPR's stock price over the past month, the longer-term underperformance highlights ongoing challenges. The company's significant net losses and decreasing revenue signal potential hurdles to achieving forecasted revenue growth of 57.32% per year. Earnings forecasts remain bleak, as CRISPR is currently unprofitable and not expected to turn profitable within the next three years. This indicates that while the recent uptick in share price might be aligned with short-term market trends, the company's underlying financial health presents uncertainties. Analyst consensus estimates a fair value price target of US$81.67, which is over twice the current share price. This suggests that the stock is trading at a substantial discount, potentially implying room for future price appreciation if the company can improve its financial metrics. However, it also underscores the risks, given the current unprofitable status and forecasted challenges ahead. Examine CRISPR Therapeutics' past performance report to understand how it has performed in prior years. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include NasdaqGM:CRSP. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Washington Post
28 minutes ago
- Washington Post
Phillies place Bryce Harper on injured list with wrist inflammation
PITTSBURGH — The scuffling Philadelphia Phillies suffered a blow Saturday when they placed first baseman Bryce Harper on the 10-day injured list because of right wrist inflammation before their game against the Pirates. Harper sat out Friday night's 5-4 loss to the Pirates. The move is retroactive to Friday. The two-time National League MVP and eight-time All-Star is hitting .258 with nine home runs, 34 RBIs and eight stolen bases in 57 games. He missed five games from May 26 to June 2 with a bruised right elbow after being hit by a pitch from Atlanta's Spencer Strider.
Bloomberg
30 minutes ago
- Bloomberg
Vance Says He Hopes Musk Will 'Come Back Into the Fold'
In a podcast interview with Theo Von "This Past Weekend", Vice President JD Vance share his thoughts Musk's exit from the Trump administration and that he hopes Musk will 'Come Back Into the Fold". (Source: Bloomberg)
